ESC 365 - Safety and tolerability of a 5 mg starting dose of vericiguat among patients with heart failure: the VELOCITY study

Open Access

Safety and tolerability of a 5 mg starting dose of vericiguat among patients with heart failure: the VELOCITY study

Session: Late-breaking science in heart failure, cardiomyopathies, pulmonary hypertension and valvular heart disease

Topic: Pharmacotherapy

Speaker: Professor S. Greene (Durham, US)

Event: Heart Failure 2025

Congress Presentation

Add to my library

About the speaker

Professor Stephen Greene

Duke Clinical Research Institute, Durham (United States of America)

14 presentations

3 followers

6 more presentations in this session

Discussant panel

Cardiopulmonary exercise testing as a novel endpoint in clinical trials on ATTR amyloid cardiomyopathy

Speaker: Doctor A. Porcari (London, GB)

Efficacy and safety of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms

Speaker: Professor I. Olivotto (Florence, IT)

Pulmonary artery denervation clinical study using the gradient denervation system in heart failure patients with pulmonary hypertension group 2

Speaker: Doctor J. Nunez Villota (Valencia, ES)

Hemodynamic effects of TX45 , a long-acting Fc-relaxin fusion, in Group 2 pulmonary hypertension patients.

Speaker: Doctor A. Muslin (Watertown, US)

Access the full session

Late-breaking science in heart failure, cardiomyopathies, pulmonary hypertension and valvular heart disease

Speakers: Professor S. Greene, Doctor A. Porcari, Professor I. Olivotto, Doctor J. Nunez Villota, Doctor A. Muslin

About the event

Heart Failure 2025

17 May - 20 May 2025

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources

Explore sponsored resources